I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Sekar Kathiresan net worth and biography

Sekar Kathiresan Biography and Net Worth

CEO of Verve Therapeutics

Dr. Sekar Kathiresan is co-founder and CEO of Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Dr. Kathiresan is a cardiologist and scientist who has focused his career on understanding the inherited basis for heart attack and leveraging those insights to improve the care of cardiovascular disease. Based on his groundbreaking discoveries in human genetic mutations that confer resistance to cardiovascular disease, Dr. Kathiresan co-founded Verve Therapeutics with a vision to create a pipeline of single-course, gene editing therapies focused on addressing the root causes of this highly prevalent and life-threatening disease. Today, Verve is advancing two initial programs that target PCSK9 and ANGPTL3, respectively – genes that have been extensively validated by Dr. Kathiresan and others as targets for lowering blood lipids, such as low-density lipoprotein cholesterol, which is a major driver of cardiovascular disease.

Prior to joining Verve, Dr. Kathiresan’s roles included director of the Massachusetts General Hospital (MGH) Center for Genomic Medicine, director of the Cardiovascular Disease Initiative at the Broad Institute and professor of medicine at Harvard Medical School. There, Dr. Kathiresan’s research laboratory focused on understanding the inherited basis for blood lipids and myocardial infarction. For his research contributions, he has been recognized by the American Heart Association with its highest scientific honor – a Distinguished Scientist Award and by the American Society of Human Genetics with the 2018 Curt Stern Award.

Dr. Kathiresan graduated summa cum laude with a B.A. in history from the University of Pennsylvania and received his M.D. from Harvard Medical School. He completed his clinical training in internal medicine and cardiology at MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.

What is Sekar Kathiresan's net worth?: The estimated net worth of Sekar Kathiresan is at least $1.76 million as of October 3rd, 2022. Dr. Kathiresan owns 317,839 shares of Verve Therapeutics stock worth more than $1,757,650 as of December 18th. This net worth approximation does not reflect any other assets that Dr. Kathiresan may own. Additionally, Dr. Kathiresan receives an annual salary of $973,250.00 as CEO at Verve Therapeutics. Learn More about Sekar Kathiresan's net worth.
How old is Sekar Kathiresan?: Dr. Kathiresan is currently 51 years old. There are 5 older executives and no younger executives at Verve Therapeutics. Learn More on Sekar Kathiresan's age.
What is Sekar Kathiresan's salary?: As the CEO of Verve Therapeutics, Inc., Dr. Kathiresan earns $973,250.00 per year. Learn More on Sekar Kathiresan's salary.
How do I contact Sekar Kathiresan?: The corporate mailing address for Dr. Kathiresan and other Verve Therapeutics executives is , , . Verve Therapeutics can also be reached via phone at 617-603-0070 and via email at [email protected]. Learn More on Sekar Kathiresan's contact information.
Has Sekar Kathiresan been buying or selling shares of Verve Therapeutics?: Sekar Kathiresan has not been actively trading shares of Verve Therapeutics within the last three months. Most recently, Sekar Kathiresan sold 50,000 shares of the business's stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $33.65, for a transaction totalling $1,682,500.00. Following the completion of the sale, the chief executive officer now directly owns 317,839 shares of the company's stock, valued at $10,695,282.35. Learn More on Sekar Kathiresan's trading history.
Who are Verve Therapeutics' active insiders?: Verve Therapeutics' insider roster includes Burt Adelman (Director), Andrew Ashe (Insider), Andrew Bellinger (Insider), and Sekar Kathiresan (CEO). Learn More on Verve Therapeutics' active insiders.
Are insiders buying or selling shares of Verve Therapeutics?: In the last twelve months, Verve Therapeutics insiders bought shares 1 times. They purchased a total of 76,000 shares worth more than $475,760.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 1,514 shares worth more than $12,475.36. The most recent insider tranaction occured on May, 14th when insider Andrew D Ashe bought 76,000 shares worth more than $475,760.00. Insiders at Verve Therapeutics own 19.3% of the company. Learn More about insider trades at Verve Therapeutics.
Information on this page was last updated on 5/14/2024.

Sekar Kathiresan Insider Trading History at Verve Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/3/2022	Sell	50,000	$33.65	$1,682,500.00	317,839
8/10/2022	Sell	50,000	$29.90	$1,495,000.00	317,839
7/19/2022	Sell	50,000	$29.90	$1,495,000.00	317,839
1/4/2022	Sell	1,870	$39.90	$74,613.00
12/28/2021	Sell	6,693	$39.90	$267,050.70
12/22/2021	Sell	57,000	$38.71	$2,206,470.00

Sekar Kathiresan Buying and Selling Activity at Verve Therapeutics

Verve Therapeutics Company Overview

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $5.09

$5.05

$5.59

50 Day Range

MA: $5.75

$4.50

$7.19

2 Week Range

Now: $5.09

$4.30

$19.34

Volume

2,051,953 shs

Average Volume

1,361,526 shs

Market Capitalization

$430.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

Sekar Kathiresan Biography and Net Worth

What is Sekar Kathiresan's net worth?

How old is Sekar Kathiresan?

What is Sekar Kathiresan's salary?

How do I contact Sekar Kathiresan?

Has Sekar Kathiresan been buying or selling shares of Verve Therapeutics?

Who are Verve Therapeutics' active insiders?

Are insiders buying or selling shares of Verve Therapeutics?